Overview

Crizanlizumab for Treating COVID-19 Vasculopathy

Status:
Completed
Trial end date:
2021-01-04
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Brigham and Women's Hospital
Novartis
Socar Research SA